Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Total Debt (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Total Debt data on record, last reported at $87.9 million in Q1 2024.

  • For Q1 2024, Total Debt rose 18.76% year-over-year to $87.9 million; the TTM value through Mar 2024 reached $87.9 million, up 18.76%, while the annual FY2025 figure was $537.0 million, 509.2% up from the prior year.
  • Total Debt reached $87.9 million in Q1 2024 per RDY's latest filing, up from $74.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $436.6 million in Q1 2022 and bottomed at $74.0 million in Q1 2023.
  • Average Total Debt over 5 years is $215.8 million, with a median of $87.9 million recorded in 2024.
  • Peak YoY movement for Total Debt: skyrocketed 425.06% in 2021, then crashed 83.05% in 2023.
  • A 5-year view of Total Debt shows it stood at $76.9 million in 2020, then surged by 425.06% to $403.7 million in 2021, then increased by 8.15% to $436.6 million in 2022, then plummeted by 83.05% to $74.0 million in 2023, then rose by 18.76% to $87.9 million in 2024.
  • Per Business Quant database, its latest 3 readings for Total Debt were $87.9 million in Q1 2024, $74.0 million in Q1 2023, and $436.6 million in Q1 2022.